Expertise in
27
conditions

Dr. Mihaela Cristea

Oncology
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
27
conditions
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 

Overview

Mihaela Cristea is an Oncologist in Duarte, California. Dr. Cristea is highly rated in 27 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Lung Cancer, Ovarian Carcinosarcoma, and Endoscopy.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

City of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer
A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: July 01, 2025
Intervention Type: Drug, Biological
Study Drugs: Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Enrollment Status: Recruiting
Publish Date: February 28, 2025
Intervention Type: Other
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug, Other
Study Drug: Cabozantinib S-malate
Study Phase: Phase 2
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other, Drug
Study Drugs: Adavosertib, Gemcitabine hydrochloride
Study Phase: Phase 2
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Cediranib maleate, Olaparib
Study Phase: Phase 2
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)
A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Biological, Other, Drug
Study Drugs: Gemcitabine, Gemcitabine Hydrochloride, Mirvetuximab Soravtansine
Study Phase: Phase 1
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Suspended
Publish Date: August 18, 2022
Intervention Type: Biological
Study Drugs: NeoTCR-P1 Adoptive Cell Therapy, Nivolumab, IL-2
Study Phase: Phase 1
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Enrollment Status: Completed
Publish Date: June 27, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Enrollment Status: Completed
Publish Date: April 30, 2018
Intervention Type: Drug, Biological, Other
Study Phase: Phase 1
View 13 Less Clinical Trials

77 Total Publications

Electrochemical and Optical Experiments and DFT Calculations of 1,4,6,8-Tetrakis((E)-2-(thiophen-2-yl)vinyl)azulene.
Electrochemical and Optical Experiments and DFT Calculations of 1,4,6,8-Tetrakis((E)-2-(thiophen-2-yl)vinyl)azulene.
Journal: Molecules (Basel, Switzerland)
Published: August 26, 2025
Similar Doctors
Alex Herrera
Expertise in
28
conditions
Dr. Alex Herrera
Oncology
Expertise in
28
conditions
Dr. Alex Herrera
Oncology

Alex Herrera, M.D.

1500 Duarte Rd, 
Duarte, CA 
 (24.0 miles away)
800-826-4673
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alex Herrera is an Oncologist in Duarte, California. Dr. Herrera has been practicing medicine for over 17 years is highly rated in 28 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
16
conditions
Dr. Alexey Danilov
Oncology
Expertise in
16
conditions
Dr. Alexey Danilov
Oncology

Alexey Danilov, M.D., PH.D.

1500 Duarte Rd, 
Duarte, CA 
 (24.0 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alexey Danilov is an Oncologist in Duarte, California. Dr. Danilov is highly rated in 16 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
21
conditions
Dr. Ravi Salgia
Oncology
Expertise in
21
conditions
Dr. Ravi Salgia
Oncology

Ravi Salgia, M.D., PH.D.

1500 Duarte Rd, 
Duarte, CA 
 (24.0 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravi Salgia is an Oncologist in Duarte, California. Dr. Salgia is highly rated in 21 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Gastrostomy.

Frequently Asked Questions about Dr. Mihaela Cristea

How do I make an appointment with Dr. Mihaela Cristea?

You can book an appointment with Dr. Mihaela Cristea by calling their office at 626-256-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mihaela Cristea a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mihaela Cristea is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mihaela Cristea specialize in?

While Dr. Mihaela Cristea is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Mihaela Cristea participate in research or clinical trials?

Yes. Dr. Mihaela Cristea has published 77 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Mihaela Cristea's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mihaela Cristea accept my insurance?

Dr. Mihaela Cristea accepts most major insurance plans, including Blue Shield of California. We recommend calling the office directly at 626-256-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cristea's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 11 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile